Clinical Trials Logo

Advanced Primary Liver Cancer clinical trials

View clinical trials related to Advanced Primary Liver Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05411757 Not yet recruiting - Clinical trials for Advanced Primary Liver Cancer

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Start date: June 30, 2022
Phase: Early Phase 1
Study type: Interventional

This is an open-label, nonrandomized investigator-initiated clinical trial to evaluate the safety, tolerability, and efficacy of IBR900 cell injection in combination with Lenvatinib or bevacizumab in subjects with advanced primary liver cancer.

NCT ID: NCT03167775 Recruiting - Clinical trials for Advanced Primary Liver Cancer

Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer

Start date: November 28, 2016
Phase: N/A
Study type: Interventional

Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer

NCT ID: NCT03166553 Recruiting - Clinical trials for Advanced Primary Liver Cancer

Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer

Start date: November 28, 2016
Phase: N/A
Study type: Interventional

Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer

NCT ID: NCT03092895 Completed - Clinical trials for Advanced Biliary Tract Carcinoma

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Start date: April 27, 2017
Phase: Phase 2
Study type: Interventional

This an open-label,Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or chemotherapy (FOLFOX4 or GEMOX regimen) in subjects with Advanced PLC.or BTC Participants with advanced PLC who failed or intolerable to prior systemic therapy will be treated with SHR-1210 plus Apatinib; Participants with advanced PLC or BTC who have never received prior systemic therapy will be treated with SHR-1210 plus FOLFOX4 or GEMOX regimen.